AZD6234 is AstraZeneca's investigational long-acting selective amylin receptor 3 (AMY3R) peptide agonist for chronic weight management, administered as a weekly subcutaneous injection. Preclinical work characterized the molecule as body-fat-selective with a differentiated tolerability profile designed to preserve lean muscle mass during weight loss.
The near-term catalyst calendar centers on the European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 through October 2, 2026. AstraZeneca is scheduled to present Phase 2 APRICUS data (AZD6234 monotherapy in obesity) plus the Phase 2b ASCEND readout (AZD6234 monotherapy, AZD9550 dual GLP-1/glucagon agonist monotherapy, or the combination against placebo over 36 weeks; NCT06862791, 377 patients). Additional Phase 2 data from ARAY (NCT06851858, AZD6234 in obesity plus type 2 diabetes on stable background GLP-1 therapy) is also expected in the same window.
Competitive positioning places AZD6234 alongside Novo Nordisk's cagrilintide (already in the CagriSema combination under FDA review), Zealand-Roche's petrelintide (Phase 3 monotherapy initiation planned late 2026), Metsera's MET-233i (Phase 1 monthly amylin), and Ascletis's ASC36 (Phase 1 monthly-to-quarterly amylin). AZD6234 is a headline asset in the AstraZeneca metabolic-disease strategy that expanded through the January 2026 $1.2 billion CSPC obesity licensing plus the earlier $18.5 billion long-acting-peptide deal with the same partner. Stories here cover clinical readouts, mechanism work, and the broader amylin agonist competitive landscape. See [[astrazeneca]], [[amylin-agonist]], and [[petrelintide]] for adjacent threads.
The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 through October 2, 2026 sets up the September obesity-peptide catalyst calendar and is anchored on the amylin agonist class. AstraZeneca will present Phase 2 APRICUS data (AZD6234 amylin analog monotherapy in obesity) plus the Phase 2b ASCEND readout (AZD6234 plus AZD9550 GLP-1/glucagon dual agonist combination against placebo over 36 weeks, 377 patients). Zealand Pharma and Roche will present petrelintide ZUPREME-2 data (obesity plus type 2 diabetes) with Phase 3 monotherapy initiation planned late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD readout window coincides with Roche's Pharma Day September 28 (updates on petrelintide, enicepatide, HM17321). Ascendis Pharma may also provide TransCon CNP achondroplasia updates. The clustered amylin data will position the class for late-2026 and 2027 regulatory and Phase 3 initiation decisions.
The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting takes place in Milan September 28 through October 2, 2026, and sets up the largest single September catalyst window for obesity-peptide investor and clinical interest. AstraZeneca will present Phase 2 data on AZD6234 (selective amylin receptor peptide agonist) monotherapy from APRICUS plus the ASCEND Phase 2b combination with AZD9550 GLP-1/glucagon dual agonist. Zealand Pharma and Roche will present petrelintide (amylin analog) data from ZUPREME-2 (obesity plus type 2 diabetes) with the Phase 3 monotherapy program preparing to initiate late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD calendar coincides with the Roche Pharma Day investor event on Monday September 28, 2026 that will update on the top-three-obesity-portfolio (petrelintide, enicepatide, HM17321). Ascendis Pharma is also expected to provide TransCon CNP achondroplasia updates.
AstraZeneca's AZD6234 (a long-acting selective amylin receptor peptide agonist, weekly subcutaneous, currently in Phase 2 for obesity and type 2 diabetes) is queued for Phase 2 data presentations at the European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 to October 2, 2026. Trials on deck: APRICUS (obesity monotherapy) primary data 'imminent' per management; ARAY (NCT06851858, AZD6234 in obesity and type 2 diabetes on stable GLP-1 background); and the ASCEND Phase 2b (NCT06862791, 377 patients) that tests AZD6234 monotherapy, AZD9550 (AZ's GLP-1/glucagon dual agonist) monotherapy, and the combination against placebo over 36 weeks. Preliminary characterization suggests body-fat-selective weight loss and a generally tolerable profile. The readouts will provide a direct comparator against Novo Nordisk's CagriSema (semaglutide plus cagrilintide) and Metsera's MET-233i (monthly amylin) and set the near-term valuation frame for AZ's metabolic disease positioning after the $1.2 billion CSPC obesity licensing announced in January.
AstraZeneca's ASCEND program is active in Phase 2b, combining AZD9550 (GLP-1 + glucagon dual agonist) with AZD6234 (selective amylin analog) in a two-molecule triple-mechanism strategy aimed at fat-selective weight loss and organ protection. Individual assets are also in Phase 2. The combination reflects the February 2026 $1.2 billion CSPC Pharmaceuticals collaboration that brought both molecules into AstraZeneca's portfolio, alongside elecoglipron (AZD5004 / ECC5004), the small-molecule oral GLP-1 that posted 5.8% weight loss over four weeks in Phase 1b in China. AstraZeneca enters the next-gen obesity race later than Lilly, Novo, Roche, and Boehringer, but the triple-mechanism positioning targets the safety + organ-protection lane that competitors leave open.